Merck skin drug succeeds in study
Merck announced its experimental drug tulisokibart significantly reduced inflammatory skin lesions in a mid-stage study for a chronic skin disease. The results boost Merck immunology pipeline and position the drug as a potential treatment.
Xurve View
Insights:
Xurve View
MERCK & CO. INC. reported that its experimental drug tulisokibart reduced inflammatory lesions by at least 50% in 72% of patients during a mid-stage study on Wednesday. The trial targets hidradenitis suppurativa, a chronic skin condition causing painful lumps. The data strengthens Merck's immunology portfolio as key patent expirations approach.
